GASTRIC ADENOCARCINOMA

This study tests whether adding tadalafil (a drug for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will take tadalafil alone for two weeks, then combined with chemo for…

This study is for people with stomach cancer that has spread to the lining of the abdomen. It compares standard chemotherapy given through a vein to the same treatment plus an extra chemotherapy drug (paclitaxel) delivered directly into the belly through a small port. The goal is…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study is for people with esophageal or gastric cancer that has spread to 3 or fewer places in the body. It compares standard chemotherapy alone to chemotherapy plus early local treatments like radiation or surgery. The goal is to see if adding local therapy helps people live…

This study tests a treatment plan for stomach cancer that has spread to the lining of the abdomen. It combines chemotherapy before surgery, a special heated chemotherapy given during a procedure called HIPEC, and surgery to remove the cancer. The goal is to see if this approach h…

This study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal i…

This study is testing whether adding two targeted drugs, pembrolizumab and trastuzumab, to standard chemotherapy can improve outcomes for people with HER2+ esophageal or stomach cancer that can be surgically removed. The treatment is given before surgery to shrink the tumor. The …

This study looks at whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach cancer from returning after surgery. It involves 460 adults with a specific type of advanced stomach cancer (PD-L1 positive, stage N3) who have had their t…

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that is HER2-positive and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-M07D1 or standard che…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread to specific lymph nodes in the back of the abdomen. About 54 participants will receive either standard treatment or a combination of …

This study tests a new drug called IMC002 in adults with advanced stomach cancer that has a specific marker (CLDN18.2) and has not responded to at least two prior treatments. About 150 participants will receive either IMC002 or a standard treatment chosen by their doctor. The goa…

This study tests a combination of an immunotherapy drug (adebrelimab) and three chemotherapy drugs given before and after surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can eliminate all cancer cells at th…

This study tests whether adding a special treatment sequence (called sequential cytoreductive intervention) to standard therapy can help people with advanced upper gastrointestinal cancers that have spread but show no detectable tumor DNA in the blood. About 54 adults with cancer…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This early-stage study tests a new treatment called DISP-10 for people with advanced colorectal, stomach, or esophageal cancers that have spread. The treatment combines a virus that may help the immune system attack cancer cells with specially engineered immune cells (CAR T cells…

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This early-phase study tests an experimental drug called BL-M05D1 in 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study is testing a mix of chemotherapy drugs and immunotherapy as a first treatment for people with advanced esophageal or stomach cancer. The goal is to see if this combination works better and causes fewer side effects than current treatments. About 52 adults with these ca…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to …

This study tests whether giving the chemotherapy drug paclitaxel before and after stomach removal surgery can help control gastric cancer that has spread to the lining of the abdomen. About 30 adults with this advanced cancer will receive the drug directly into the abdomen and th…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or junction cancer that can be removed. The goal is to see if the combination is safe and works well enough to …

This study looks at people with esophageal or stomach cancer that has spread to only a few places (oligometastases). All participants get 4 months of standard drug therapy, then are randomly assigned to either have local treatment (surgery or radiation) right away or after anothe…

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This study looks at how well a drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The cancer must have a specific protein (claudin 18.2) on its surface. The goal is to see i…

This early-phase trial tests a new drug called AVA6103 in about 144 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors to kill cancer cells while limiting…

This study tests a new way to treat stomach cancer that has spread to the lining of the abdomen. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the belly during surgery. The goal is to help patients recover faster and have few…

This early-stage study tests whether adding a drug called aldesleukin (IL-2) to standard immunotherapy and chemotherapy can better control stomach cancer that has spread to the abdomen lining. About 15 adults with this condition will receive the combination. The goal is to see if…

This study tests a new combination treatment for people with advanced stomach, esophageal, or gastroesophageal junction cancer that has not responded to standard therapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into their tumor during a scope …

This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…

This study compares a new stool test that looks for high-risk gene changes in H. pylori bacteria with a standard risk questionnaire to see which method finds stomach cancer earlier. Researchers will enroll 15,000 adults aged 40 and older. Participants will provide a stool sample …

This study looks at whether removing drainage tubes after laparoscopic stomach cancer surgery helps patients recover faster without increasing complications. About 454 adults with early to advanced stomach cancer will be randomly assigned to receive standard care with drains or a…

This study is building a registry of people with early stomach changes that can lead to cancer, such as gastric atrophy or intestinal metaplasia. Researchers will also include healthy people and those with stomach cancer for comparison. The goal is to learn what makes these early…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday practice in Germany. It will include about 1,900 adults starting their first palliative therapy. The goal is to unders…